Website Information
    Web Site Information :.   Site Info    Whois    Traceroute    RBL Check  

Enter Web Site URL Address:
 

evolutiopharma.com: Estudios y Analisis farmacolgicos. Evolutio Pharma
evolutiopharma, anlisis.  
 
 

Estudios y Analisis farmacolgicos. Evolutio Pharma

Description: evolutiopharma, anlisis.

Keywords: farmacia, estudios farmacolgicos, datos farmacologicos, anlisis farmacologicos

Tags: evolutiopharma, del, estudios, farmacolgicos, anlisis, evolutio, analisis, pharma, naranja=mantenimiento, verde=subida, rojo=, bajada, farmacologicos, magnitudes, datos, febrero, una, zbs, acumulado, farmacia, potencial, salud, internacionales, studio, gya, web, las, torno, informes, documentacin, base, organizada, desarrollo, contacto, quienes, privacidad, politica, copyright, somos, mapa,

Evolutiopharma.com

Content Revalency: Title: 16.67%   Description: 50.00%   Keywords: 16.67%  |  Document size: 10,313 bytes
More info: Whois - Trace Route - RBL Check
 
EVOLUTIOPHARMA.COM - Site Location
Country/Flag ES Spain
City/Region/Zip Code , ,
Organization arsys.es
Internet Service Provider arsys.es
 
EVOLUTIOPHARMA.COM - Domain Information
Domain EVOLUTIOPHARMA.COM   [ Traceroute  RBL/DNSBL lookup ]
Registrar Arsys Internet, S.L. dba NICLINE.COM Arsys Internet, S.L. dba NICLINE.COM
Whois server whois.verisign-grs.com
Created 20-Jul-2009
Updated 20-Jul-2020
Expires 20-Jul-2021
Time Left 0 days 0 hours 0 minutes
Status ok https://icann.org/epp#ok ok https://www.icann.org/epp#ok
DNS servers DNS1.GYASOLUTIONS.COM   82.223.172.132
DNS2.GYASOLUTIONS.COM   82.223.173.127
 
EVOLUTIOPHARMA.COM - DNS Information
IP Address 217.76.130.206 ~ Whois - Trace Route - RBL Check
Domain Name Servers dns1.gyasolutions.com   82.223.172.132
dns2.gyasolutions.com   82.223.173.127
Mail Exchange smtp-02.servidoresdns.net   217.76.128.139
 
Site Response Header
Response HTTP/1.1 200 OK
Server Apache
Date Mon, 11 Apr 2011 09:04:53 GMT
Content-Type text/html


  IP Index    TLD Index    Domain Index    Site Index New   Copyright © 2024 Cybernet Quest.